Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study.

ABSTRACT:

Introduction

Healthcare systems are looking to reduce their carbon impact. Short-acting β₂-agonist (SABA) overuse (≥ 3 canisters/year) is common in asthma and linked to poor outcomes; however, its environmental impact remains unknown. As part of the CARBON programme, this study retrospectively quantified the carbon footprint of SABA and controller inhalers across all respiratory indications and SABA overuse in asthma in lower-middle-income countries (LMICs), upper-middle-income countries and high-income countries across Africa, Asia Pacific, Latin America and the Middle East.

Methods

Two data sources were utilised to evaluate the carbon contribution of inhalers to respiratory care. To quantify greenhouse gas (GHG) emissions associated with total inhaler use across

SUBMITTER: Alzaabi A 

PROVIDER: S-EPMC10567885 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature